Nemtabrutinib clinical trials
Nemtabrutinib is named as an intervention in 8 current clinical trials in our USA, China, Turkey, Brazil, UK, Germany, Spain, Poland, Canada, Israel, Australia, Italy, Czechia, Portugal, Japan, Denmark, Mexico, Taiwan, Ireland, Sweden, South Korea, Singapore, France, Belgium, Switzerland and Norway registers. 4 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Merck Sharp & Dohme LLC (7). The most-studied condition is Chronic Lymphocytic Leukemia. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
How Nemtabrutinib works
All drug targets →- B-cell chronic lymphocytic leukemiaPhase 3
- LeukemiaPhase 3
- Lymphoid leukemiaPhase 3
- Richter transformationPhase 2
- Waldenstrom macroglobulinemiaPhase 2
- Diffuse large B-cell lymphomaPhase 2
- Follicular lymphomaPhase 2
- Mantle cell lymphomaPhase 2
- Marginal zone lymphomaPhase 2
- Hematopoietic and lymphoid cell neoplasmPhase 1/2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4756476, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 11413, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Nemtabrutinib
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Nemtabrutinib
8 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Nemtabrutinib in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Nemtabrutinib. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
FILOCLL017 - NEVOTAL : Nemtabrutinib in addition to Venetoclax-Obinutuzumab in chronic lymphocytic leukemia (CLL) / small lymphocytic leukemia (SLL) patients with TP53 ALterations
2026-525763-40-00 · Hemic and Lymphatic Diseases
|
Phase 2 | Authorised | French Innovative Leukemia Organization (F.I.L.O.) | France |
Conditions studied with Nemtabrutinib
18 conditionsAll 18 conditions
| Condition (as registered) | Trials |
|---|---|
| Chronic Lymphocytic Leukemia | 4 |
| Small Lymphocytic Lymphoma | 3 |
| Mantle Cell Lymphoma | 1 |
| Follicular Lymphoma | 1 |
| Richter Transformation Lymphoma | 1 |
| Hematologic Malignancies | 1 |
| Waldenstroms Macroglobulinaemia | 1 |
| Non-Hodgkins Lymphoma | 1 |
| Chronic Lymphocytic Leukaemia | 1 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 |
| Leukemia, Chronic Lymphocytic | 1 |
| Small-Cell Lymphoma | 1 |
| Lymphoma, Small Lymphocytic | 1 |
| Severe Renal Impairment | 1 |
| Healthy | 1 |
| Lymphoma, B-Cell | 1 |
| Waldenstrom Macroglobulinemia | 1 |
| Hematological Malignancies | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 7 |
| ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 1 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Nemtabrutinib trials
How many clinical trials are testing Nemtabrutinib?
8 current trials in our USA, China, Turkey, Brazil, UK, Germany, Spain, Poland, Canada, Israel, Australia, Italy, Czechia, Portugal, Japan, Denmark, Mexico, Taiwan, Ireland, Sweden, South Korea, Singapore, France, Belgium, Switzerland and Norway registers name Nemtabrutinib (also registered as MK-1026) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Nemtabrutinib trials recruiting patients?
Yes. 4 of the 8 trials are recruiting: 4 with sites in USA, 2 with sites in China, 3 with sites in Turkey, 3 with sites in Brazil, 3 with sites in UK, 3 with sites in Germany, 3 with sites in Spain, 2 with sites in Poland, 3 with sites in Canada, 3 with sites in Israel, 3 with sites in Australia, 2 with sites in Italy, 2 with sites in Czechia, 2 with sites in Portugal, 2 with sites in Japan, 2 with sites in Denmark, 2 with sites in Mexico, 2 with sites in Taiwan, 1 with sites in Ireland, 1 with sites in Sweden, 1 with sites in South Korea, 2 with sites in France, 2 with sites in Belgium, 1 with sites in Switzerland and 1 with sites in Norway. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Nemtabrutinib clinical trials?
Merck Sharp & Dohme LLC (7) and ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) (1). The number in brackets is how many trials each organisation leads.
Are there Nemtabrutinib clinical trials in Ireland?
Yes. 2 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Nemtabrutinib works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Nemtabrutinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Nemtabrutinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.